IXC
Click for more information
8.33% 6.5¢ invex therapeutics ltd

Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-154

  1. TheDerivative
    343 Posts.
    lightbulb Created with Sketch. 23
    clock Created with Sketch.
    18/11/21
    22:40
    Post #: 57687262
    I would have thought at least $2 or somewhere around $150M market cap for where we are in terms of trial status. There’s such a large disconnect from where we are and where we should be and this is what I’ve been struggling with for the last 18 months - regardless of the FDA approval.
    what is a miss? It’s the $100M question?!?


    IXC Price at posting: 62.0¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

LLL Leo Lithium announces major divestment of flagship Goulamina project to Ganfeng
right-arrow Created with Sketch.
EMD Emyria and UWA secure $499,411 grant to advance MDMA analogue drug program
right-arrow Created with Sketch.
EX1 Tryptamine Therapeutics completes maiden dosing of IV psilocin – a global first
right-arrow Created with Sketch.
LRV Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%
right-arrow Created with Sketch.
NEWS Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker
right-arrow Created with Sketch.
NEWS Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25
right-arrow Created with Sketch.
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
6.5¢ 		Change
0.005(8.33%) 		Mkt cap ! $4.885M
Open High Low Value Volume
6.5¢ 6.5¢ 6.5¢ $1.02K 15.68K

Buyers (Bids)

No. Vol. Price($)
1 31311 6.6¢
 

Sellers (Offers)

Price($) Vol. No.
7.7¢ 7950 1
View Market Depth
Last trade - 10.07am 02/07/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.